Ischemix, Inc. is developing novel, proprietary cytoprotective compounds for the treatment of serious neurological diseases and conditions. Our lead compound, CMX-2043, is in preclinical development for the treatment of traumatic brain (TBI) and for ischemic stroke. CMX-2043 has produced the strongest preclinical data of any compound in development for TBI, as demonstrated by significant findings in controlled preclinical studies of sensorimotor activity, cognition, memory, contusion volume and hyperactive behaviour, as well as by biochemical assays. With respect to ischemic stroke, CMX-2043 has demonstrated significance in the improvement of mitochondrial respiration in a preclinical model of global ischemia. Ischemix had previously shown favorable results in a preliminary study of CMX-2043 in a preclinical model of regional ischemic stroke (MCAO).
Because the etiology of TBI and stroke are similar, Ischemix believes this combination of results is very encouraging. We also plan to study our compound as a prophylactic for TBI. Futher, there is reason to believe that our compound could be therapeutic candidate to slow the progression of Alzheimer's disease.
CMX-2043 is a new chemical entity with a multi-modal activity that is well-suited for the complex conditions of TBI and ischemic stroke. CMX-2043 is the subject of multiple issued composition of matter and method of use patents around the world.Learn more →